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EVALUATING THE UTILITY OF SPECT/CT IMAGING OF ANGIOSOME 
PERFUSION IN DIABETIC PATIENTS WITH CRITICAL LIMB ISCHEMIA. 
Jessica L. Buckley, Albert J. Sinusas, Mitchel R. Stacy. Section of Cardiovascular 
Medicine, Department of Internal Medicine, Yale University School of Medicine, New 
Haven, CT.  
 
Impaired lower extremity perfusion is a hallmark of peripheral arterial disease 
(PAD) and is particularly problematic in diabetic patients, who suffer from high rates of 
PAD, ulceration, and lower extremity amputation. The ability to non-invasively detect 
deficits in microvascular perfusion within vascular territories, or angiosomes, of the feet 
may provide information related to tissue viability and guide therapeutic interventions. In 
this study, we sought to apply single photon emission computed tomography 
(SPECT)/CT imaging to quantify volumetric microvascular perfusion within specific 
angiosomes containing non-healing foot ulcers in diabetic patients with critical limb 
ischemia (CLI). Additionally, we sought to assess the value of SPECT/CT perfusion 
imaging for predicting limb salvage in CLI patients undergoing lower extremity 
endovascular revascularization.  
Forty-one diabetic patients (mean age, 66±12 yrs) with non-healing ulcers and 
nine healthy control subjects (mean age, 50±10 yrs) underwent SPECT/CT imaging of 
the feet following a resting injection of technetium-99m (99mTc)-tetrofosmin (dose, 550.6 
± 37 Mbq). CT images of diabetic feet were segmented into five angiosomes and used for 
quantifying relative radiotracer uptake, expressed as standardized uptake values (SUVs). 
SUVs were assessed for each CLI patient in the angiosome containing the non-healing 
ulcers, while average whole foot perfusion was assessed for healthy control subjects. 
Percent change in SPECT SUVs of ulcerated angiosomes was quantified following 
 
	
endovascular revascularization in patients, and 3-, 6-, and 12-month limb salvage 
outcomes were assessed. 
SPECT/CT imaging allowed for visualization of perfusion deficits under resting 
conditions. 99mTc-tetrofosmin SPECT/CT imaging of angiosome foot perfusion 
demonstrated a significant difference in baseline perfusion values (SUVs) between 
diabetic patients with CLI and healthy control subjects (p = 0.02). Analysis of baseline 
SPECT/CT imaging and ankle-brachial index (ABI) measurements in CLI patients and 
healthy control subjects demonstrated a significant and positive relationship between 
SPECT/CT angiosome perfusion and ABI (p = 0.01; r = 0.41). Serial evaluation of 
relative changes in SPECT angiosome foot perfusion following revascularization 
revealed significant quantitative changes in perfusion after treatment, whereas ABI 
measurements did not demonstrate significant changes after revascularization. Changes in 
SPECT/CT-derived angiosome perfusion significantly differed between patients with and 
patients without amputation in the 3 (p = 0.01), 6 (p = 0.03), and 12 (p = 0.03) months 
following revascularization. 
SPECT/CT imaging provides a useful non-invasive tool for evaluating 
microvascular perfusion within specific angiosomes of the foot under resting conditions. 
SPECT/CT imaging also allows for serial assessment of sensitive changes in angiosome 
microvascular perfusion following revascularization that are undetected by ABI. 
Perfusion imaging with SPECT/CT offers a novel quantitative imaging approach for 
assessing the efficacy of revascularization strategies targeted at restoring perfusion to 
non-healing wounds of the foot and may assist with predicting limb salvage outcomes in 
CLI patients undergoing revascularization. Future application of SPECT/CT perfusion 
 
	
imaging may provide additional value for detection and targeting of ischemic tissue for 
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INTRODUCTION 
Peripheral Arterial Disease 
 Peripheral arterial disease (PAD) is a manifestation of atherosclerosis and is 
commonly defined as a partial or complete obstruction of at least one noncoronary blood 
vessel (3, 4). PAD affects approximately 8 million Americans (5) and it is estimated that 
the worldwide prevalence of PAD is 10 percent (6). It is estimated that PAD affects 
greater than 200 million people worldwide (3); however, it is likely that many more may 
have PAD given that individuals may be asymptomatic. PAD has an increased prevalence 
among males and the elderly. Furthermore, the prevalence of PAD increases above 10 
percent in individuals over the age of 60 (3). A study approximated the annual cost of 
PAD related treatment at 4.37 billion dollars (7). PAD patients are at a high risk for 
having a cardiovascular event and the majority die of cardiac or cerebrovascular-related 
events (8).  
 PAD manifests in a wide spectrum of symptoms. Individuals with PAD can be 
asymptomatic or have clinical manifestations ranging from intermittent claudication to 
limb-threatening ischemia, rest pain, non-healing ulcers, and gangrene. The most 
common presentation of PAD is a patient suffering from intermittent pain or cramping in 
the legs and/or feet during exercise or exertion that is relieved with rest, which is referred 
to as intermittent claudication. The more severe end of the PAD spectrum, rest pain and 
non-healing ulcers, and/or gangrene is called critical limb ischemia (CLI). Outcomes for 
patients with CLI are alarming, at 1 year, 10 percent will experience a fatal 
cardiovascular event and 25 percent will have had an amputation (9). Aggressive 
treatment is needed for these patients since progression to amputation is common. CLI 
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results in a mortality rate of 46 percent at 5 years and amputations occur in 27 percent of 
patients within the first year (10). 
 Asymptomatic patients are typically identified after a suspicious physical exam 
that identifies weak or absent pedal pulses. Suspected PAD can be confirmed with a 
commonly used clinical tool called an Ankle-Brachial Index (ABI). The resting ABI is 
obtained by measuring systolic blood pressures at the arms (brachial arteries) and ankles 
(dorsalis pedis and posterior tibial arteries) in the supine position by using a Doppler 
device. The ABI of each leg is calculated by dividing the higher of the dorsalis pedis or 
posterior tibial pressure by the higher of the right or left arm blood pressure. The normal 
range for an ABI is 0.9-1.3. Patients with lower extremity claudication will commonly 
score below 0.9, however, patients with calcified vessels, especially diabetic patients will 
often have falsely elevated ABIs because of the inability to properly compress their 
vessels during this exam.  
 Apart from physical 
exam there are several scoring 
systems that exist to classify 
PAD patients according to their 
symptoms, with the most 
commonly used system in the 
United States being the 
Rutherford system, outlined in Figure 1 (1).  
 Risk factors for PAD echo those of coronary artery disease, namely, family 
history, diabetes mellitus (DM), smoking, hypertension, hyperlipidemia (9). However, 
 
 
Figure 1. Classification systems for PAD patients (1).  
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DM and smoking are the most strongly associated with worse PAD outcomes outside of 
other risk factors. DM, in particular, is associated with more clinical complications, such 
as lower extremity amputations and higher mortality (8).  
Role of Diabetes Mellitus in PAD 
 In 2010, there were 25.8 million people in the United States with DM (11). In 
2011, it was estimated that 350 million people worldwide were affected by DM (12). The 
prevalence of DM in the United States has increased by an alarming 382 percent from 
1988 to 2014 (13) and is strongly related with the rise in obesity, where 85.2 percent of 
individuals with type 2 DM are overweight or obese (14). Diabetic foot complications are 
the leading cause of hospitalization and major or minor amputation, and these 
complications represents up to 40 percent of health expenditures in DM patients (12). 
DM is a risk factor for PAD, with PAD prevalence rates of 10-40 percent in the DM 
patient population (15). DM doubles the chance of developing PAD and it has been 
shown that a 1 percent increase in glycated hemoglobin A1c (HA1c), an indicator of 
long-term glycemic exposure, is associated with a 26 percent increase in developing PAD 
(6, 16). In comparison with patients without DM, PAD is more likely to progress in 
patients with DM.  
 In addition to an increased prevalence of PAD in the setting of DM, DM patients 
also have a 12-15 percent risk of developing foot lesions, making DM an important risk 
factor for limb amputation (17). Alarmingly, patients with concomitant PAD and DM are 
5 to 10 times more likely to have disease progression requiring an amputation (6). DM 
foot lesions may start as an uncomplicated area, but risk for amputation increases with 
the development of infection in soft tissue (cellulitis) and bones (osteomyelitis). Eight 
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five percent of amputations are preceded by foot ulcers that subsequently evolve to 
severe infection and gangrene, ultimately resulting in 5-8 percent of patients with DM 
foot complications undergoing major amputation within 1 year of presentation (12). 
Additionally, patients with concurrent PAD and DM foot ulcers experience high 
mortality rates, where 50 percent of patients will be dead within 5 years of clinical 
presentation (15).  
 In several large observational studies, PAD was present in up to 50 percent of the 
patients with diabetic foot ulcers and was an independent risk factor for amputation (15). 
The poor outcomes of ischemic foot ulcers in those with DM is thought to be due to a 
combination of factors including, but not limited to, the anatomic distribution of vascular 
lesions rendering them more difficult to treat, the association with other abnormalities 
such as infection, neuropathy, renal failure, and abnormalities in other vascular territories 
such as coronary and cerebral arteries (15). Wound healing is further disturbed by the 
complex interaction of several factors, such as poor glycemic control, microvascular 
dysfunction, impaired collateral vessel formation, abnormal mechanical loading of the 
ulcer, and co-morbidities (15). It is estimated that early detection and appropriate 
treatments may prevent up to 85 percent of these amputations (11). A non-invasive 
imaging approach able to assess microvascular function in PAD patients is needed but 
more so in those with concomitant diabetes for whom the combination of pathology 
results in severe and harsh outcomes in a short period of time.  
Overview of Diagnostic Tools 
 Several non-invasive tools have been used to detect and evaluate PAD, including 
the ankle-brachial index (ABI), toe-brachial index (TBI), Transcutaneous oxygen 
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pressure (TcPO2), duplex ultrasound, magnetic resonance (MR) imaging, computed 
tomography (CT) angiography, single-photon emission computed tomography (SPECT), 
and positron emission tomography (PET).  Currently, the ABI is the most recognized 
and most widely applied functional measurement used for diagnosis and therapy 
monitoring (18). In patients with a history or physical examination suggestive of PAD, 
the ABI has good validity as a first-line test in the diagnosis of PAD, as shown by 
vascular imaging, with sensitivities ranging from 68 to 84 percent and specificities from 
84 to 99 percent (18). However, ABI measurements have disadvantages. Specifically, 
ABI is only truly effective at evaluating large vessel obstructions and therefore has 
decreased sensitivity in the setting of microvascular disease, can be falsely elevated in 
patients with calcified arteries, and has poor reproducibility due to inter-user variability 
(7, 19). Of note, approximately 30 percent of CLI patients have normal or near-normal 
ABI measurements (19). Additionally, the accuracy of using the ABI for predicting 
healed foot ulcers has been shown to be low, with a sensitivity of 0.48 (95% CI, 0.36-
0.61) and specificity of 0.52 (95% CI, 0.42-0.63) (11).  
 Where ABI fails to obtain an accurate measurement in patients with calcified 
arteries, toe-brachial index (TBI) may prove to be a better choice. TBI is obtained in a 
similar manner to ABI but uses great toe systolic pressures in the place of ankle and foot 
pressures. TBI is useful when ABI measure are thought to be inaccurate or cannot be 
obtained because digital arteries are not compressible (19). However, similarly to ABI, 
TBI do not localize disease and is not a viable tool in many patients with progressed 
disease who have already had their great toes amputated.  
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 TcPO2 has been used to assess microcirculation and assist in PAD diagnosis (19). 
TcPO2 uses a non-invasive diagnostic tool applied to the epidermal surface of the skin to 
determine the pO2 level in tissues (20). However, TcPO2 has limited accuracy in the 
setting of edema, thick skin, infection, and is time consuming (19). The greatest 
weakness of TcPO2 as an assessment tool is its ability to only measure superficial tissue 
viability (7). For ulcer healing, the combined sensitivity and specificity of TcPO2 have 
been shown to be 0.72 (95% CI, 0.61-0.81) and 0.86 (95% CI, 0.68-0.95), respectively 
(11).  
 For lower extremity anatomical assessment, duplex ultrasound, CT angiography 
and MR angiography are routinely used in clinical practice to detect PAD and identify the 
location and extent of arterial obstruction. Due to the non-invasive nature, lower risks, 
and lower costs, duplex ultrasound is frequently the primary imaging modality used in 
patients with PAD; however, ultrasound is not without limitations. Specifically, 
ultrasound only permits evaluation of blood flow in major vessels and is not useful for 
the assessment of collateral vessel flow (7). Additionally, ultrasound is particularly 
challenging in the obese patient with arterial calcifications due to image shadowing (19). 
Clinical studies have shown that the quality of ultrasound depends on the user’s level of 
experience and that some arterial segments are more easily visible than others. (21). For 
example, in some cases (i.e. obesity, gas interpositions), the iliac arteries are more 
difficult to visualize and alternative methods, such as CT angiography, MR angiography, 
and digital subtraction angiography should be considered (22). CT and MR angiography 
can both offer valuable anatomical information. The great advantage of CT angiography 
remains the visualization of calcifications, clips, stents, and bypasses (22). CT 
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angiography requires exposure to radiation and iodinated contrast material and its utility 
is reduced when it comes to calcified vessels, particularly in the smaller vessels of the 
calf and foot (19). In comparison to CT angiography, MR angiography does not require 
radiation or iodinated contrast (19). However, MR angiography does use gadolinium 
contrast agents, which cannot be used in cases of severe renal insufficiency (GFR, 30 
mL/min per 1.73 m2) (22), and MR is hindered in the presence of non-compatible 
pacemakers or metal implants (including stents). 
 Digital subtraction angiography (DSA) remains the gold standard for imaging 
tools in assessing PAD since it allows for high spatial resolution imaging of vascular 
occlusions (6). DSA is an invasive procedure and carries the risk of complications, 
including hematoma, pseudoaneurysm, dissection and arteriovenous fistula (6). 
Additionally, DSA requires intra-arterial delivery of iodinated contrast, and is limited in 
its inability to characterize vessel walls and thrombus (6). Replacing DSA with a non-
invasive alternative may reduce contrast-induced nephrotoxicity, patient discomfort, and 
reduce patient costs. Considered as the gold standard for decades, DSA is now reserved 
for patients undergoing peripheral interventions, especially concomitant to endovascular 
procedures (22). CT and MR angiography are now replacing DSA as routine secondary 
imaging methods since they permit a non-invasive assessment of the localization and 
extension of vascular lesions and facilitate accurate planning of endovascular and/or 
surgical treatment (10).  
Assessment of Lower Extremity Perfusion 
 Since impaired lower extremity perfusion is the main pathophysiological 
mechanism of PAD, imaging tools capable of non-invasively evaluating tissue perfusion 
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can be invaluable for ongoing assessment of disease progression and treatment success. 
The ability to detect microvascular foot abnormalities may be particularly valuable in the 
setting of diabetes, where patients commonly present with concomitant macro- and 
microvascular disease. Although studies have attempted to assess perfusion, imaging 
modalities such as ultrasound and TcPO2 only look at 2D slices, superficial perfusion, or 
have not been readily adopted owing to lengthy acquisition times and reproducibility 
concerns (20, 23). Additionally, these tools do not permit quantitative volumetric 
assessment of tissue oxygenation or perfusion within different vascular territories of the 
foot. Therefore, a clinical need exists for a non-invasive imaging tool capable of 
assessing global changes in foot tissue perfusion. 
 SPECT/CT perfusion imaging of the lower extremities can be performed under 
resting conditions and provides quantitative assessment of microvascular perfusion 
within three-dimensional (3D) vascular territories, or angiosomes, of the foot. The ability 
to identify volumetric abnormalities in microvascular perfusion under resting conditions 
can be of significant value in the CLI patient population since many of these patients are 
incapable of ambulating for exercise stress testing. SPECT/CT perfusion imaging can be 
performed without the need of an intravenous contrast agent, thus offering a useful non-
invasive approach for evaluating perfusion in diabetic patients who also commonly 
present with impaired renal function.  
 Nuclear imaging modalities provide high sensitivity and offer potentially novel 
methods for the investigation of PAD. SPECT and PET are the primary nuclear imaging 
modalities. SPECT imaging also allows for the simultaneous evaluation of multiple 
radiotracers targeted at various physiological processes. PET imaging provides increased 
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sensitivity and resolution and generally involves perfusion radiotracers with shorter half-
lives, resulting in lower levels of ionizing radiation exposure to patients; however, 
SPECT is more established, less expensive, and more widely available (5). Both SPECT 
and PET not only allow for the physiologic assessment of PAD but may also permit 
evaluation of molecular events associated with disease progression or treatment response. 
Although SPECT and PET provide higher sensitivity, they both also have lower spatial 
resolution when compared with CT and MR (submillimeter to ~1 mm resolution) (5). 
However, the recent emergence of hybrid SPECT/CT and PET/CT systems has allowed 
for the combination of high sensitivity physiologic SPECT and PET imaging with high 
resolution anatomic imaging of CT to optimally localize and quantify radiotracer uptake. 
Additionally, these hybrid imaging systems now permit correction of attenuation and 
partial-volume effects, allowing for more precise radiotracer quantification within 
anatomically defined regions of interest (24).  
 The first nuclear medicine studies examining lower extremity skeletal muscle 
blood flow in PAD patients evaluated the clearance rates of 24Na-Chloride, 133Xe, and 
99mTc-pertechnetate after an intramuscular injection of these radiotracers (25-27). The 
development of nuclear medicine later led to two-dimensional imaging of microspheres 
and albumin that were radiolabeled with 99mTc, 131I-sodium, and 111In to measure lower 
extremity perfusion (28-30). These techniques were not ideal as they required intra-
arterial injections in order to evaluate blood flow during first pass circulation. The need 
for techniques that did not require intra-arterial injections eventually led to the use of 
thallium-201 (201Tl) as a perfusion agent for SPECT imaging. 201Tl is a diffusible tracer 
with properties similar to potassium, thereby allowing for transport into viable cells via 
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the sodium–potassium pump (31). This makes the tracer uptake a reliable measure of 
both myocardial and skeletal muscle perfusion (32-36). 201Tl perfusion imaging can 
provide an estimate of flow over a wide physiologic range since it can be performed after 
an intravenous injection at rest or during exercise and has a high first-pass extraction 
(~85%) (33). Whole-body 201Tl scintigraphy has been shown to be useful for evaluating 
perfusion abnormalities in the lower extremities of PAD patients at rest and during 
exercise, and for the detection of perfusion abnormalities in asymptomatic patients 
presenting with normal ankle brachial indices (35-37). PAD severity has traditionally 
been assessed by determining ratios of activity between non-stenotic and stenotic legs or 
by normalizing activity in lower extremity regions of interest to whole-body activity in 
the presence of bilateral disease (32, 37, 38). With the emergence of 3D SPECT imaging 
systems, it was possible to more accurately detect and localize regions of lower extremity 
ischemia under both rest and stress conditions with 201Tl (34). One of the first lower-
extremity imaging studies to use 201Tl SPECT for the investigation of PAD evaluated 
stress profile curves from multiple transverse images in the leg during reactive hyperemia 
with normalization of regional activity to whole-body activity (34). Although 201Tl was 
shown to be effective in many studies, its long half-life and imaging characteristics were 
less favorable when compared with technetium-99m (99mTc)-labeled radiotracers (5). 
This has resulted in the implementation of newer 99mTc-labeled perfusion tracers that 
reduce radiation exposure and provide better image quality (7). 99mTc-labeled compounds 
demonstrate little redistribution, which allows for injections during exercise and 
measures of peak exercise perfusion at a delayed imaging time (39). Additionally, the 
biodistrubtion and kinetics of these compounds make it possible to perform lower 
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extremity perfusion measurements in combination with myocardial perfusion assessment 
(38). One 99mTc-labeled tracer in particular, 99mTc-sestamibi, has been incorporated in 
several studies examining lower extremity perfusion in PAD. It has revealed improved 
sensitivity for detecting differences in resting perfusion between the lower extremities of 
patients with unilateral disease and greater sensitivity when compared with Doppler 
ultrasound for detection of PAD (5). Preliminary data from our lab have shown that 
SPECT/CT imaging with 99mTc-tetrofosmin also has potential for assessing regional 
differences in lower extremity perfusion in PAD patients with abnormal CT angiography 
and ABI findings (5). SPECT/CT has detected perfusion abnormalities in the calves of 
diagnosed PAD and asymptomatic patients, with a sensitivity (91%) and specificity 
(94%) for the diagnosis of PAD while correlating well with angiographic and Doppler 
findings (34, 37, 40).  
 To date, non-invasive imaging approaches for evaluating foot perfusion in PAD 
patients have been primarily limited to assessment of superficial tissue or require 
physiologic stressors. PET/CT imaging may be an option to assess lower extremity 
perfusion but thus far has not been applied for evaluating foot perfusion and remains 
costly due to the need for more expensive instrumentation, including an onsite cyclotron 
or portable generator for isotope production (41-43). SPECT/CT perfusion imaging 
which could be easily combined with clinically indicated myocardial perfusion imaging 
can be performed under resting conditions and provides quantitative assessment of 
microvascular perfusion within 3D angiosomes of the foot containing non-healing ulcers 
that are targeted for revascularization. The ability to identify volumetric abnormalities in 
microvascular perfusion under resting conditions can be of significant value in the CLI 
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patient population since many of these patients have poor tolerance for and are unable to 
ambulate for treadmill exercise stress testing. SPECT/CT perfusion imaging can be 
performed without the need of an intravenous contrast agent, thus offering a useful non-
invasive approach for evaluating lower extremity perfusion in high risk diabetic patient 
who also commonly present with coexisting impaired renal function. SPECT/CT imaging 
may allow for improved assessment of diabetic patients at baseline and following 
treatment, such as lower extremity revascularization. Our research team at Yale 
University was the first to demonstrate the feasibility of using SPECT/CT imaging to 
track serial changes in resting microvascular perfusion within 3D muscle groups of the 
lower extremities (44). Additionally, we have developed and clinically translated 
SPECT/CT image analysis tools for quantifying regional differences in skeletal muscle 
perfusion into the calf muscles of patients with unilateral PAD (5). 
PET imaging can also assess lower extremity blood flow in PAD patients (41, 42, 
45-47). The primary PET radiotracer implemented in patient studies has been 15O-H2O. 
It can freely diffuse into tissue and has a short half-life (~2 min), making it useful for 
repeated measurements of blood flow in a single visit, at rest and during exercise, or 
during vasodilator stress (41-43, 45, 47-49). An 15O-H2O rest–stress PET study found 
significant differences in flow reserve within the calves of PAD patients when compared 
with healthy volunteers (41). Another study found significantly reduced exercise-induced 
muscle blood flow in the distal legs of PAD patients who were referred for lower 
extremity amputation (45). These findings suggested that 15O-H2O PET imaging may be 
a valuable tool for determining subsequent amputations (45). Another group, Kalliokoski 
et al., showed that PET assessment of blood flow and oxygen uptake in lower extremity 
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skeletal muscle may be a useful tool for evaluating responses to exercise (43). However, 
they observed substantial variability in baseline PET flow measurements and therefore 
additional assessment tools such as angiography may be required for thorough evaluation 
of PAD patients. PET imaging of preclinical animal models of PAD have been used to 
evaluate lower extremity rest and stress blood flow and have demonstrated a high 
correlation between PET and microsphere-derived blood flow values (46, 50). In a 
murine model of PAD, PET imaging with 13N-ammonia has been used to assess acute 
and chronic changes in lower extremity perfusion, showing a close correlation between 
PET perfusion results and histologic analysis of tissue fibrosis and necrosis (46). 
Although PET imaging has proven to be useful for evaluating the lower extremities, the 
short half-life of available tracers can also present a limitation for PET imaging. PET 
stress imaging has traditionally required the use of exercise ergometers that are attached 
to scanners, as images must be acquired during or immediately after exercise. The 
development of an 18F-labeled perfusion agent (flurpiridaz) for myocardial perfusion 
assessment, however, may assist with exercise PET imaging of both the heart and the 
lower extremities. The longer half-life (~110 min) allows for tracer injection during peak 
treadmill exercise and then serial evaluation of myocardial and skeletal muscle stress 
perfusion. The high extraction fraction of 18F-flurpiridaz in the myocardium may offer 
an advantage for evaluating lower extremity skeletal muscle blood flow but this 
possibility still needs to be established (51).  
 In the present study, we further translate SPECT/CT imaging to evaluate resting 
microvascular perfusion within 3D foot angiosomes in diabetic patients with CLI using a 
recently developed approach for segmentation of CT attenuation images of the foot (52). 
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In addition to our novel approach for 3D segmentation of the foot and analysis of 
angiosome perfusion, we translate previously developed image registration tools to assess 
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STATEMENT OF PURPOSE 
Background and Motivation 
 Impaired lower extremity perfusion is a hallmark of peripheral arterial disease 
(PAD) and is particularly problematic in the setting of diabetes mellitus (DM), which is 
associated with high rates of PAD, foot ulceration, and lower extremity amputation. The 
ability to non-invasively detect deficits in microvascular perfusion within three-
dimensional (3D) vascular territories, or angiosomes, of the feet may provide information 
related to tissue viability and guide future therapeutic interventions. In this study, the 
overarching goal was to evaluate the utility of single photon emission computed 
tomography (SPECT)/CT imaging for quantifying volumetric microvascular perfusion 
within specific angiosomes of the foot containing non-healing ulcers in DM patients with 
critical limb ischemia (CLI). 
 
Hypotheses and Aims 
Hypothesis 1: SPECT/CT imaging of microvascular perfusion in foot angiosomes 
provides a quantitative approach for assessing underlying pathophysiology of the foot 
under resting conditions. 
Aim 1: Compare resting angiosome perfusion between healthy volunteers and diabetic 
patients with critical limb ischemia using SPECT/CT imaging.  
 
Hypothesis 2: SPECT/CT imaging of angiosome microvascular perfusion does not 
correlate with a standard clinical index, the ankle-brachial index (ABI), which is 
commonly used to assess macrovascular disease of the lower extremities. 
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Aim 2: Evaluate the relationship between SPECT/CT imaging of angiosome 
microvascular perfusion and the ankle-brachial index, a clinically validated tool for the 
assessment of PAD. 
 
Hypothesis 3: SPECT/CT imaging allows for sensitive detection of regional changes in 
microvascular perfusion within specific ulcerated angiosomes following lower extremity 
revascularization and may predict short-term and long-term clinical outcomes. 
Aim 3: Evaluate the utility of SPECT/CT imaging for assessing relative changes in 
angiosome microvascular perfusion following lower extremity revascularization in 
diabetic patients with critical limb ischemia and relate serial changes in angiosome 
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METHODS  
Subject Recruitment 
 A prospective single-center study was 
performed in 41 adult patients (age, 66 ± 12 
years) with peripheral arterial disease and 
diabetes. All patients suffered from critical limb 
ischemia in the form of non-healing foot ulcers or 
resting pain in the foot and/or calf. Inclusion 
criteria for patients included patients 18 years or 
older with previously diagnosed diabetes (type I 
or II), based on any of the following criteria: 
fasting plasma glucose greater than 126 mg/dl on 
2 separate occasions, glycated hemoglobin 
(HbA1c) greater than 6.5%, two-hour plasma 
glucose ≥200 mg/dL in an oral glucose tolerance test; previously established history of 
peripheral arterial disease via abnormal Ankle-Brachial Index (<0.9 or ³1.3), history of 
lower extremity rest pain, tissue loss, or presence of non-healing ulcer. Upon enrollment, 
demographic information, clinical history, and location and severity of any non-healing 
ulcers were documented. Patients scheduled for lower extremity peripheral angiography 
as part of their assessment and treatment were prospectively enrolled into the study. An 
illustration of our subject enrollment considerations is shown in Figure 2.  
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 Healthy control subjects (n=9) were also recruited from Yale University, Yale-
New Haven Hospital, and the greater New Haven area using a research flyer. They were 
screened using a standard medical history questionnaire and a physical activity 
questionnaire. Subjects who did not have any exclusion criteria including preexisting 
coronary artery disease, peripheral arterial disease, diabetes, cancer, hypertension, 
smoking history, proceeded with standard PAD screening. PAD screening included 
Ankle-Brachial Indices (ABIs) of both lower extremities. Additionally, in order to screen 
for major coronary 
disease, we recorded 
subjects’ resting blood 
pressure and heart rate. 
Inclusion and exclusion 
criteria are described in 
Figure 3.   
 Yale University’s Human Investigation Committee and Radiation Safety Board 
approved the study protocol and informed consent was obtained from all patients and 
healthy volunteers.  
 
 
Figure 3. Healthy Control and CLI subject inclusion and exclusion 
criteria for enrollment. 
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Clinical SPECT/CT Imaging Protocol 
 All patients and healthy volunteers underwent baseline single photon emission 
computed tomography (SPECT)/CT perfusion imaging of the lower extremities at Yale-
New Haven Hospital’s Nuclear Cardiology clinical laboratory using a standard clinical 
imaging protocol, following the American Society of Nuclear Cardiology guidelines. All 
SPECT/CT images were acquired at the level of the ankle and foot using a conventional 
hybrid SPECT/4-slice CT imaging system with large field-of-view sodium iodide (NaI) 
detectors (Infinia Hawkeye, GE Healthcare) using a 360º step and shoot acquisition with 
a 140.5 keV±10% window, 3º 
projections, and 30 seconds per 
stop. All subjects received a low 
dose (14.9 ± 1.0 mCi, 551.3 ± 37 
MBq) intravenous injection of 
technetium-99m (99mTc)-
tetrofosmin under resting conditions and underwent SPECT/CT imaging 15 minutes 
following radiotracer injection (Figure 4). Immediately following the SPECT acquisition, 
CT images were acquired with a slice thickness of 5 mm, at 140 kVp, and 2.5 mA for the 
purposes of attenuation correction and future image segmentation of foot angiosomes.  
 Diabetic patients with CLI who were scheduled for lower extremity 
revascularization therapy (balloon angioplasty and/or stenting) underwent additional 
99mTc-tetrofosmin SPECT/CT perfusion imaging 1 to 3 days post-procedure, prior to 
hospital discharge, to examine relative changes in microvascular perfusion in the 
angiosome containing the non-healing foot ulcer.  
 
 
Figure 4. SPECT/CT Imaging Protocol.  
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 All SPECT images were reconstructed using iterative reconstruction applying 
corrections for attenuation, scatter, and resolution loss. SPECT/CT images were 
reconstructed using system software (Xeleris, GE Healthcare, Buckinghamshire, UK) 
capable of generating co-registered functional (SPECT) and anatomical (CT) maps of the 
feet. SPECT images were reconstructed and fused with CT attenuation images.  
SPECT/CT Image Analysis 
 SPECT/CT images were analyzed using 
an image analysis toolkit (BioImage Suite, 
http://www.bioimagesuite.org) developed at 
Yale University and previously utilized for 
regional assessment of lower extremity tissue 
perfusion and oxygenation (2, 5, 44, 52, 54, 55) 
Low-dose CT attenuation images were used to 
segment and define five angiosomes of the feet 
(lateral plantar, medial plantar, lateral calcaneal, medial calcaneal, dorsal foot; Figure 5). 
Average radiotracer uptake was assessed from co-registered SPECT images within the 
CT-defined three-dimensional (3D) angiosome containing the non-healing ulcer. Average 
SPECT intensity values for the angiosome containing the non-healing ulcer were 
normalized to injected dose of radiotracer (mCi) and patient body weight (kg) to generate 
standardized uptake values (SUVs). In healthy volunteers who did not have foot 




Figure 5. Volume rendered foot 
angiosomes overlaid on CT attenuation 
images. A) Medial, B) lateral, and C) 
posterior views display the medial heel 
(orange), lateral heel (yellow), dorsal foot 
(green), medial plantar (blue), and lateral 
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 In diabetic patients who underwent SPECT/CT perfusion imaging before and after 
lower extremity revascularization, serial images were co-registered using an automated 
approach of rigid and non-rigid image registration previously developed and published 
within the principal investigator’s laboratory thus ensuring serial perfusion analysis of the 
same 3D angiosome before and after revascularization (52, 53). Changes in angiosome 
perfusion were ultimately expressed as the percent change in SUV from baseline to post-
revascularization. 
Evaluation of Clinical Outcomes 
 Rates of re-intervention, wound healing, and limb salvage were evaluated in CLI 
patients at 3, 6, and 12 months following lower extremity revascularization. Percent 
changes in SPECT angiosome perfusion were compared between patients who underwent 
an amputation versus patients who did not undergo an amputation in the first 3, 6, and 12 
months following lower extremity revascularization.   
99mTc-tetrofosmin SPECT/CT Imaging and Radiation Safety 
 Due to concerns regarding the amount of ionizing radiation that patients receive 
with diagnostic imaging, it is prudent that all measures be taken to maintain the ALARA 
(as low as reasonably achievable) principle. A low-dose (~15 mCi) injection of 99mTc-
tetrofosmin, which possesses a relatively short half-life of 6 hours, is associated with ~3 
mSv of ionizing radiation, while CT attenuation scans of the feet immediately after the 
SPECT acquisition are associated with ~0.3-0.4 mSv, thus making total exposure similar 
to that of PET/CT perfusion imaging. Total radiation doses remained well within current 
standard clinical limits. Of note, CT images were acquired at the level of the foot and 
ankle where no vital organs were exposed to X- rays and associated radiation risk was 
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low.  
Statistical Analysis 
 Unpaired t-tests were used to identify differences in baseline SPECT perfusion 
values (i.e. SUVs) and baseline ABIs between healthy volunteers and diabetic patients 
with CLI. Pearson’s correlation coefficient was used to assess the relation between 
baseline SPECT perfusion values and baseline ABI measurements. A paired t-test was 
used to identify differences between the SPECT and ABI responses to revascularization 
in diabetic patients. Unpaired t-tests were used to identify differences between SPECT 
perfusion changes for patient groups (amputation or no amputation) at each outcome time 
point (3, 6, and 12 months after revascularization). All statistical analyses were 
performed using commercially available software (GraphPad Prism v6.0 for Mac OS X, 
GraphPad Software, La Jolla, CA). Statistical significance for all analyses was set at P < 
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RESULTS 
A total of 41 diabetic patients 
with CLI and 9 healthy control subjects 
were recruited into the study. Subject 
group characteristics are summarized in 
Table 1. The healthy control subjects 
presented with normal ABIs and did not 
have a history of diabetes or other 
cardiovascular co-morbidities. The CLI 
patients were on average obese, 
presented with abnormal ABI measures, 
and had numerous cardiovascular co-
morbidities, such as a history of 
smoking.  
Of the 41 CLI patients initially scheduled for endovascular revascularization 




Patient retention is 
illustrated in Figure 6. 
	
	
Table 1. Demographics of diabetic patients with CLI 
and healthy control subjects. *, significantly 
different from control subjects (p < 0.0.5).  
 
 
Figure 6. CLI Patient Recruitment.  
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 Significant differences in ABI 
measurements between CLI patients (0.62 ± 
0.22, n = 29) and healthy control subjects (1.05 
± 0.11, n = 9) confirmed the presence of PAD in 
the diabetic patient population (p < 0.0001; 
Figure 7). Of note, only 29 of 41 recruited CLI 
patients had ABI measurements available. 
SPECT/CT Imaging of Baseline Angiosome 
Perfusion 
 99mTc-tetrofosmin SPECT/CT imaging 
of perfusion within specific angiosomes containing non-healing ulcers demonstrated a 
significant difference in baseline perfusion 
values (SUVs) between diabetic patients 
with CLI and healthy control subjects (p = 
0.02; Figure 8).  
SPECT/CT perfusion imaging 
revealed the appearance of decreased foot 
perfusion in CLI patients who presented 
with multiple signs of lower extremity 
disease (Figure 9), including non-healing 
foot ulcers (Figure 9A, 9B), decreased 
pressure waveforms (Figure 9C), and 
arterial occlusion (Figure 9D).  
 
 
Figure 7. Comparison of ABI in healthy 
control subjects and diabetic patients with 
CLI. Healthy control subjects 
demonstrated significantly higher ABI 




Figure 8. Comparison of SPECT perfusion in 
healthy control subjects and diabetic patients 
with CLI. Baseline SPECT SUVs in the feet of 
healthy subjects were significantly higher than 
SUVs in foot angiosomes containing non-













Correlation of SPECT/CT Perfusion Imaging with Standard Assessment Tools 
Analysis of baseline SPECT/CT 
imaging and ABI measurements in CLI 
patients and healthy control subjects 
demonstrated a significant and positive 
relationship between SPECT/CT angiosome 
perfusion and ABI (p = 0.01; r = 0.41; 
Figure 10).  
Evaluation of Serial Changes in Angiosome 
Perfusion Using SPECT/CT Imaging 
SPECT/CT imaging of CLI patients 
undergoing lower extremity endovascular 
revascularization demonstrated the ability to detect resting deficits in angiosome foot 
	
 
Figure 9. A) Dorsal and B) plantar views of a non-healing ulcer in a patient with 
C) decreased pressure waveforms and D) superficial femoral artery occlusion, as 
identified by angiography (occlusion denoted by yellow arrow). E) Sagittal, F) 
axial, and G) coronal SPECT/CT images reveal decreased resting perfusion in 




Figure 10. Relationship between ABI and 
baseline SPECT perfusion. ABI was 
significantly and positively related to baseline 
SPECT SUVs when collectively assessing 
healthy controls and CLI patients; however, 
more scatter among CLI patient data points 
suggests a weaker relationship in the setting of 
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perfusion before intervention 
within areas of ulceration 
(Figure 11A, 11B), as well as 
allowed for visualization of 
improvements in angiosome 
perfusion following 
revascularization (Figure 11C).  
Serial evaluation of 
relative changes in SPECT 
angiosome foot perfusion 
following revascularization revealed significant quantitative changes in perfusion after 
treatment (Figure 12) whereas ABI measurements did not demonstrate significant 












Figure 11. SPECT/CT perfusion imaging in diabetic patient 
with CLI before and after lower extremity revascularization 
treatment. A) Patient displaying diabetic non-healing ulcer on 
plantar aspect of right great toe. B) Axial SPECT/CT 
perfusion images demonstrate perfusion defect in region of 
right great toe before revascularization (ischemic area 
denoted by white arrows). C) SPECT/CT perfusion imaging 
after revascularization demonstrates increased perfusion to 




Figure 13. Evaluation of serial changes 
in ABI in CLI patients undergoing 
revascularization. ABI measures did not 





Figure 12. Evaluation of serial changes 
in SPECT SUVs in CLI patients 
undergoing revascularization. SPECT 
SUVs showed a significant increase 
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Of note, only 24 of 41 recruited CLI patients had post-procedure SPECT/CT imaging and 
only 9 of 41 recruited CLI patients had ABI measurements taken before and after 
revascularization procedure. 
Clinical Outcomes 
 Long-term follow-up of CLI patients at 12 months demonstrated 68 percent of 
patients had an at least one major (above the ankle) or minor (below the ankle) ampuation 
(Figure 14A). 19.5 percent of patients were deceased at 12 months (Figure 14B). 19.5 
percent of patients had evidence that their initial wounds had healed (Figure 14C). Note, 
this is not to say they did not develop subsequent wounds. 48.7 percent of patients had 
 
 
Figure 14. CLI patients’ clinical outcomes 12 months after baseline SPECT/CT 
imaging. (A) 12 months after baseline imaging, 68 percent of CLI patients had 
undergone a major (above the ankle) or minor (below the ankle) amputation, (B) 19.5 
percent were deceased, (C) 19.5 percent experienced wound healing, and (D) 48.7 
percent of patients required at least one re-intervention procedure. n=41 CLI patients. 
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undergone at least one revasculariztion intervention due to restenosis, new symptoms 
such as ischemic rest pain, or new non-healing wounds (Figure 14D).  
 Of the 24 CLI patients who had post-procedure SPECT/CT imaging, 11 had an 
amputation within 3 months after revascularization (Figure 15A). There was a significant 
difference between the percent changes in angiosome perfusion following 
revascularization in patients with (4.99 ± 3.44%) and patients without (14.2 ± 11.3%) 
amputation in the first 3 months post-procedure (Figure 15A; p = 0.01).  
 In the 6 months after procedure, 13 of the 24 CLI patients who underwent 
revascularization had undergone an amputation. Again, the percent changes in SPECT 
angiosome perfusion were significantly higher in the patients who had not undergone an 
amputation (14.4 ± 12.3%) in the first 6 months post-revascularization compared to 
patients who did have an amputation (6.24 ± 4.53%) (Figure 15B; p = 0.03). 
 In the 12 months after revascularization, 14 of the 24 CLI patients who underwent 
revascularization had undergone an amputation. Again, the percent changes in SPECT 
perfusion were significantly higher in patients who had not undergone an amputation 
 
 
Figure 15. Changes in SPECT-derived angiosome foot perfusion in relation to limb salvage outcomes. The percent 
change in SPECT SUVs after revascularization were significantly different between CLI patients who experienced limb 
salvage compared to patients who underwent a minor or major lower extremity amputation in the (A) 3, (B) 6, and (C) 
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(14.8 ± 12.8%) in the first 12 months after revascularization versus patients who 






















- 30 - 
DISCUSSION 
 In the present study, we demonstrate for the first time the utility of SPECT/CT 
perfusion imaging for non-invasive assessment of angiosome microvascular perfusion 
under resting conditions, as well as following lower extremity endovascular 
revascularization. We demonstrate that SPECT/CT imaging is sensitive for detecting 
perfusion abnormalities in diabetic patients with CLI and that baseline SPECT/CT 
perfusion imaging correlates loosely with a standard clinical index, the ABI. 
Additionally, we demonstrate that SPECT/CT imaging allows for serial assessment of 
relative changes in microvascular perfusion within angiosomes of the foot containing 
non-healing ulcers following lower extremity revascularization, and that angiosome 
specific changes in SPECT perfusion may relate to clinical outcomes such as rates of 
limb salvage.  
 In the assessment of baseline angiosome foot perfusion, SPECT/CT perfusion 
imaging demonstrated significantly higher perfusion values in the feet of healthy control 
subjects when compared to ulcerated foot angiosomes of diabetic patients with CLI 
(Figure 8), thus indicating sensitivity of SPECT/CT imaging for detecting PAD 
pathology. The presence of PAD was confirmed in diabetic patients with CLI by using a 
standard clinical index, the ABI, which revealed significant differences between healthy 
and CLI patients (Figure 7). Prior studies have utilized SPECT/CT imaging for 
assessment of PAD patients; however, this study presents a novel image segmentation 
tool that allows for unique SPECT/CT imaging of regional angiosome foot perfusion 
under resting conditions in a CLI patient population at high risk for lower extremity 
amputation (7, 56, 57). Correlational analysis demonstrated a significant and positive 
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relationship between baseline SPECT SUVs and ABI measurements in the collective 
assessment of CLI patients and healthy control subjects; however, the relationship 
between SPECT perfusion and ABI was clearly more scattered when looking specifically 
at CLI patient data points (Figure 10). This finding is consistent with previous studies 
that have demonstrated ABI is limited in utility when assessing the diabetic patient 
population, which is likely due to the high prevalence of microvascular disease and 
calcification (58). Additionally, the looser relationship between SPECT and ABI within 
CLI patients may be suggestive of a mismatch between microvascular perfusion (as 
assessed by SPECT) and large vessel obstruction (as assessed by ABI) in the diabetic 
patient population. 
In addition to evaluating the utility of SPECT/CT imaging for baseline assessment 
of angiosome foot perfusion, we have demonstrated the value and sensitivity of 
SPECT/CT imaging for assessing the effect of lower extremity revascularization in 
diabetic patients with CLI. To facilitate serial assessment of changes in angiosome 
perfusion following treatment, we have translated previously developed tools for serial 
image registration, which allow for reproducible assessment of perfusion within the same 
3D segmented angiosomes (52, 53). Following lower extremity revascularization, our 
SPECT/CT imaging approach demonstrated significant changes in angiosome perfusion 
(Figure 12) that were not observed when utilizing the ABI (Figure 13), a standard clinical 
tool utilized for assessing PAD patients. This data suggests that SPECT/CT perfusion 
imaging is sensitive for non-invasively detecting changes in microvascular perfusion 
following medical treatment, and that SPECT/CT imaging may offer benefits over the 
standard ABI, which primarily assesses macrovascular pressures/patency and can be 
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limited in utility in the setting of arterial calcification or microvascular disease. 
Additionally, the ability of SPECT/CT imaging to evaluate microvascular perfusion 
might be of particular relevance in the diabetic patient population since diabetic patients 
commonly suffer from concomitant macrovascular and microvascular, with the latter 
being a key contributor to the formation and impaired healing process of diabetic foot 
ulcers (58).  
 Long-term follow-up of CLI patient outcomes at 12 months post-revascularization 
demonstrated similar clinical outcomes to those previously reported in clinical trials aside 
from our amputation rates, which were slightly higher (8). This may be a reflection of 
wound severity in our CLI patient populating, in particular, infection and the fact these 
patients were already scheduled for intervention perhaps indicating wound severity. 
Specifically, 68 percent of patients had an at least one major (above the ankle) or minor 
(below the ankle) ampuation (Figure 14A), while 19.5 percent of patients were deceased 
by 12 months (Figure 14B) and only 19.5 percent experienced wound healing (Figure 
14C). Additionally, 48.7 percent of patients required at least one additional 
revasculariztion procedure due to restenosis, new symptoms such as ischemic rest pain, 
or new non-healing wounds (Figure 14D). This data is in agreement with prior clinical 
studies that have demonstrated similar rates of re-intervention in the CLI patient 
population (8, 59). 
 Prior research studies have applied non-invasive imaging for the evaluation of 
responses to medical treatment in PAD patients, however, to date, there has been a lack 
of clinical studies that have related findings from non-invasive imaging to clinical 
outcomes (60, 61). In the present study, we found that our SPECT/CT imaging approach 
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may possess strength as a tool for predicting clinical outcomes, such as limb salvage. 
Specifically, we found that patients who experienced poor improvements in angiosome 
perfusion following revascularization (i.e. 5 to 6 percent) ultimately experienced a minor 
or major amputation of the lower extremity, whereas patients experiencing greater 
improvements in angiosome perfusion (i.e. 14 to 15 percent) experienced limb salvage up 
to 3, 6, and 12 months after revascularization procedure (Figure 15). These findings 
suggest that SPECT/CT perfusion may possess significant value for the assessment of 
treatment responses in PAD patients and could assist clinical decisions in the time period 
immediately following medical treatment.   
To date, non-invasive imaging approaches for evaluating foot perfusion in PAD 
patients have been primarily limited to assessment of superficial tissue or require 
physiologic stressors (22). CT and MR angiography can both offer valuable anatomical 
information, however, CT angiography requires exposure to radiation and iodinated 
contrast material and its utility is reduced in the setting of calcified vessels, particularly in 
the smaller vessels of the calf and foot (19). In comparison to CT angiography, MR 
angiography does not require radiation or iodinated contrast, but MR angiography does 
use gadolinium contrast agents, which cannot be used in cases of severe renal failure. 
Additionally, MR is hindered in the presence of non-compatible pacemakers or metal 
implants (including stents) (19, 22). DSA remains the gold standard for imaging tools in 
assessing PAD since it allows for high spatial resolution imaging of vascular occlusions, 
but it is an invasive procedure and carries the risk of complications, including hematoma, 
pseudoaneurysm, dissection and arteriovenous fistula (6). Additionally, it requires intra-
arterial delivery of iodinated contrast, and is limited in its inability to characterize vessel 
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walls and thrombus (6). PET/CT imaging may be an option to assess lower extremity 
perfusion but thus far has not been applied for evaluating foot perfusion and remains 
costly due to the need for more expensive instrumentation (41-43). SPECT/CT perfusion 
imaging could be easily combined with clinically indicated myocardial perfusion 
imaging, can be performed under resting conditions, and provides quantitative assessment 
of microvascular perfusion within 3D angiosomes of the foot containing non-healing 
ulcers that are targeted for revascularization. Many CLI patients are unable to ambulate 
for treadmill exercise stress testing and many of these high-risk patients also commonly 
present with impaired renal function. Therefore, the ability to derive potentially valuable 
clinical information in CLI patients under resting conditions without the need for an 
intravenous contrast agent may lead to lower extremity SPECT/CT perfusion imaging 
becoming a clinically valuable tool in the near future. 
 One limitation of this study is the imaging approach has not been fully validated. 
We could validate this approach by evaluating test-retest reliability. In the future we 
could also expand our imaging approach to assess patients along the entire spectrum of 
PAD and not just the most severe cases, such as CLI. Additionally, we may investigate 
the utility of stress SPECT/CT perfusion imaging of the lower extremity which could be 
combined with clinically indicated cardiac perfusion imaging.  
 In the present study, we apply SPECT/CT imaging to evaluate resting 
microvascular perfusion within 3D foot angiosomes in diabetic patients with CLI using a 
recently developed approach for segmentation of CT attenuation images of the foot (52). 
In addition to our novel approach for 3D segmentation of the foot and analysis of 
angiosome perfusion, we translate previously developed image registration tools to assess 
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serial changes in perfusion within segmented angiosomes following revascularization 
(53). Lastly, we show SPECT/CT imaging of angiosome perfusion may be able to predict 
short- and long-term limb salvage outcomes for CLI patients undergoing lower extremity 
revascularization procedures. Therefore, our results demonstrate that, 99mTc-tetrofosmin 
SPECT/CT perfusion imaging may be useful for the evaluation of various types of 
targeted therapies in PAD, such as revascularization procedures, exercise therapy, and 
novel gene therapies. Additionally, SPECT/CT imaging may be useful in assessing early 
response to treatment, thereby providing clinicians with an early indication of treatment 
efficacy and potentially guiding further treatment. Future application of SPECT/CT 
imaging may provide additional value for detection of ischemic regions of the foot, as 
well as assist with risk stratification. Further evaluation of the sensitivity of SPECT/CT 
imaging in predicting wound healing and limb salvage in a large clinical trial of PAD 
patients undergoing medical treatment is warranted and could elucidate the true clinical 
utility of this imaging approach. 
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